Program

The program runs from 9:30 AM to 3:30 PM (UTC+3, Finnish time).

9:30 Welcome to the Webinar!
Anja Isoaho, Training Manager, Pharmaca Health Intelligence
Moderator: Tatu Sainio, Market Access Director & Commercial Lead, Finland, Bristol Myers Squibb

09:40 Overview and Current Status of the New EU HTA Regulation 
Ruta Janeckaite, Legal Officer, Directorate-General for Health and Food Safety, European Commission

10:10 European Landscape: Progress and Perspectives
• Summary of developments across EU countries
• Are countries aligned or diverging?
• Monitoring goal achievement
• Experiences from the First Joint Clinical Assessments (JCAs)
Matteo Scarabelli, Associate Director, Market Access, EFPIA European Federation of Pharmaceutical Industries and Associations

11:10 Break

11:30 Patient Perspective in HTA at EU and National Level
Mirjami Tran Minh, Senior Planning Officer, Finnish Cancer Center FICAN

11:55 Lunch Break

13:00 National HTA Agencies’ Preparation for the Implementation of the EU HTA Regulation
Moderator: Akseli Kivioja, HEMAR Manager/HTA Strategy Lead, Johnson & Johnson

Tuomas Oravilahti, Chief Specialist, Finnish Medicines Agency Fimea
Hjalte Holm Andersen, Senior Medical Assessor, Danish Medicines Council

14:00 Break

14:30 Practical Implementation of JCAs and Related Challenges 
Herbert Altmann, VP, Market Access & Healthcare Consulting Europe, PharmaLex

15:15–15:30 Closing Remarks
Tatu Sainio, Market Access Director & Commercial Lead, Finland, Bristol Myers Squibb
Anja Isoaho, Training Manager, Pharmaca Health Intelligence